Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017

M Neil Reaume¹, Naveen S Basappa², Lori Wood³, Anil Kapoor^{4

5}, Georg A Bjarnason⁶, Normand Blais⁷, Rodney H Breau⁸, Christina Canil¹, Patrick Cheung⁹, Henry J Conter¹⁰, Sebastien J Hotte¹¹, Claudio Jeldres¹², Michael A S Jewett¹³, Pierre I Karakiewicz¹⁴, Christian Kollmannsberger¹⁵, Francois Patenaude¹⁶, Alan So¹⁷, Denis Soulières⁷, Peter Venner², Phillippe Violette⁴, Pawel Zalewski¹⁸, Heather Chappell¹⁹, Scott A North²; Kidney Cancer Research Network of Canada

Affiliations

¹ Division of Medical Oncology, Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, ON, Canada.
² Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada.
³ Department of Medicine and Urology, Dalhousie University, Halifax, NS, Canada.
⁴ Division of Urology, McMaster University, Hamilton, ON, Canada.
⁵ The Kidney Cancer Research Network of Canada, Toronto, ON, Canada.
⁶ Division of Medical Oncology/Hematology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
⁷ Division of Medical Oncology/Hematology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
⁸ Clinical Epidemiology Program and Division of Urology, Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada.
⁹ Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
¹⁰ William Osler Health System, Brampton, ON, Canada.
¹¹ Juravinski Cancer and McMaster University, Hamilton, ON, Canada.
¹² Centre hospitalier de l'Université de Sherbrooke, Sherbrooke, QC, Canada.
¹³ Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
¹⁴ Service d'urologie, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
¹⁵ Division of Medical Oncology, British Columbia Cancer Agency-Vancouver Cancer Centre, and University of British Columbia, Vancouver, BC, Canada.
¹⁶ Department of Medicine, Hematology Service and Department of Oncology, Sir Mortimer B. Davis Jewish General Hospital and McGill University, Montreal, QC, Canada.
¹⁷ Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
¹⁸ R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, ON, Canada.
¹⁹ Kidney Cancer Canada, Toronto, ON, Canada.

PMID: 29382441
PMCID: PMC5963441
DOI: 10.5489/cuaj.4769

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017

M Neil Reaume et al. Can Urol Assoc J. 2017 Oct.

. 2017 Oct;11(10):310-320.

doi: 10.5489/cuaj.4769.

Authors

Affiliations

¹ Division of Medical Oncology, Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, ON, Canada.
² Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada.
³ Department of Medicine and Urology, Dalhousie University, Halifax, NS, Canada.
⁴ Division of Urology, McMaster University, Hamilton, ON, Canada.
⁵ The Kidney Cancer Research Network of Canada, Toronto, ON, Canada.
⁶ Division of Medical Oncology/Hematology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
⁷ Division of Medical Oncology/Hematology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
⁸ Clinical Epidemiology Program and Division of Urology, Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada.
⁹ Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
¹⁰ William Osler Health System, Brampton, ON, Canada.
¹¹ Juravinski Cancer and McMaster University, Hamilton, ON, Canada.
¹² Centre hospitalier de l'Université de Sherbrooke, Sherbrooke, QC, Canada.
¹³ Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
¹⁴ Service d'urologie, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
¹⁵ Division of Medical Oncology, British Columbia Cancer Agency-Vancouver Cancer Centre, and University of British Columbia, Vancouver, BC, Canada.
¹⁶ Department of Medicine, Hematology Service and Department of Oncology, Sir Mortimer B. Davis Jewish General Hospital and McGill University, Montreal, QC, Canada.
¹⁷ Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
¹⁸ R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, ON, Canada.
¹⁹ Kidney Cancer Canada, Toronto, ON, Canada.

PMID: 29382441
PMCID: PMC5963441
DOI: 10.5489/cuaj.4769

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Reaume has been an advisor for Astellas, Pfizer, and Roche; has received grants/honoraria from AstraZeneca, Ferring, Merck, Novartis, and Sanofi; and has participated in clinical trials supported by Novartis, Pfizer, and Roche. Dr. Basappa has been an advisor for Astellas, AstraZeneca, BI, BMS, Janssen, Novartis, and Pfizer; and has received honoraria from Astellas, BMS, Janssen, Novartis, and Pfizer. Dr. Wood has been an advisor for Astellas, BMS, Novartis, and Pfizer. Dr. Kapoor has been an advisor for and participated in clinical trials supported by Amgen, Astellas, Janssen, GSK, Novartis, Pfizer, and Sanofi. Dr. Bjarnason has received grants and honoraria from BMS, Merck, Novartis, and Pfizer. Dr. Blais has received consulting honoraria from BMS, Merck, Novartis, Pfizer, and Roche. Dr. Canil has been an advisor for Astellas, Bayer, BMS, Esai, Merck, Pfizer, Roche, and Sanofi; received an educational grant from Pfizer; and participated in clinical trials supported by AstraZeneca, Bayer, Janssen, Medivation, and Roche. Dr. Cheung has received investigator-initiated grants from Abbvie, Aventis, Pfizer and Sanofi. Dr. Conter has been an advisor for Novartis and Pfizer. Dr. Hotte has been an advisor for AstraZeneca, BMS, Merck, and Pfizer; and has participated in clinical trials supported by AstraZeneca, BMS, Merck, and Takeda. Dr. Jewett has been an advisor for Pfizer and Theralase; a consultant for Olympus, Pfizer, and Theralase; and holds investments in Theralase. Dr. Karakiewicz has been an advisor for Pfizer; has received payment for advisory board presentations from AbbVie, Astellas, Ferring, Janssen, and Pfizer; and has received a research grant from Pfizer. Dr. So has been a speaker for Amgen, Astellas, and Janssen. Dr. Soulières has been an advisor for Novartis and Pfizer; and has participated in clinical trials supported by Merck and Pfizer. Dr. Venner has been an advisor for Astellas, Novartis, Pfizer, and Sanofi; has received speaker honoraria from Astellas; and has participated in clinical trials supported by Astellas, BMS, and Exelixis. Dr. Violette has been an advisor for Janssen and a speaker for Astellas, Janssen, Pfizer, and Sanofi. Dr. Zalewski has participated in clinical trials supported by BMS, Janssen, Pfizer, and Roche. Dr. North has been an advisor for Astellas; received honoraria from Astellas, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Roche, and Sanofi; and participated in clinical trials supported by Astellas, Roche, and Sanofi. The remaining authors report no competing personal or financial interests.

References

1. Canadian Kidney Cancer Forum. Management of kidney cancer: Canadian Kidney Cancer Forum consensus statement. Can Urol Assoc J. 2008;2:175–82. - PMC - PubMed
1. Canadian Kidney Cancer Forum. Management of kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J. 2009;3:200–4. doi: 10.5489/cuaj.1069. - DOI - PMC - PubMed
1. Jewett M, Finelli A, Kollmannsberger C, et al. Management of kidney cancer: Canadian Kidney Cancer Forum consensus update 2011. Can Urol Assoc J. 2012;6:16–22. doi: 10.5489/cuaj.11273. - DOI - PMC - PubMed
1. North S, Basappa N, Bjarnason G, et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 consensus update. Canadian Urol Assoc J. 2013;7:238–43. doi: 10.5489/cuaj.536. - DOI - PMC - PubMed
1. North SA, Basappa N, Basiuk J, et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J. 2015;9:164–70. doi: 10.5489/cuaj.2894. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017

Affiliations

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017

Authors

Affiliations

Conflict of interest statement

References

LinkOut - more resources

Full Text Sources

Other Literature Sources